NVDA vs PFE: Which Is the Better Buy?
Side-by-side comparison of NVIDIA Corporation and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-21.
NVIDIA Corporation · Technology
$219.76
+45.0% upside to fair value
Grade B
High Quality
VS
Pfizer Inc. · Healthcare
$26.33
+28.6% upside to fair value
Grade B
QuantHub Verdict
NVDA has more upside to fair value
(+45.0%).
PFE trades at a lower forward P/E
(19.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
NVDA |
PFE |
| Current Price |
$219.76 |
$26.33 |
| Fair Value Estimate |
$318.65 |
$33.85 |
| Upside to Fair Value |
+45.0%
|
+28.6%
|
| Market Cap |
$5,322.7B |
$149.8B |
| Forward P/E |
33.4x
|
19.3x
|
| EV / EBITDA |
27.6x
|
12.9x
|
| Price / Sales |
21.0x
|
2.4x
|
| Price / FCF |
44.7x
|
16.5x
|
| Revenue Growth YoY |
+85.2%
|
-1.2%
|
| Gross Margin |
74.1%
|
70.3%
|
| Operating Margin |
64.0%
|
24.7%
|
| Return on Equity |
111.7%
|
8.7%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.24%
|
6.06%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
NVIDIA Corporation is a leading technology company specializing in semiconductors, primarily known for its GPUs and AI accelerators that power gaming, data center, and professional visualization markets. The company benefits from a durable competitive moat driven by its founder-led management, strong insider alignment, and dominant market share in AI data center chips. NVIDIA's business quality i…
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
Accumulation Zones
| Metric |
NVDA |
PFE |
| Zone Low |
$238.99 |
$25.39 |
| Zone High |
$270.85 |
$28.77 |
| In Buy Zone? |
Yes
|
Yes
|